Anti-Diabetes Drugs - Southeast Asia

The Anti-Diabetes Drugs market in Southeast Asia is anticipated to witness a substantial increase in revenue, projected to reach US$1.35bn by 2024.
This market is expected to exhibit a steady growth rate of 7.94% annually from 2024 to 2029, leading to a market volume of US$1.98bn by 2029.
When compared to other regions worldwide, United States is forecasted to generate the highest revenue in the Anti-Diabetes Drugs market, amounting to US$37.84bn in 2024.
The Southeast Asian market for anti-diabetes drugs is experiencing a surge in demand due to the region's rising prevalence of diabetes.

Definition:
The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Drugs to treat diabetes mellitus (oral intake and injections)
Insulin
Non-insulinotropic anti-diabetic drugs

Drugs to treat other metabolic disorders or other autoimmune diseases
Lipid-lowering agents
Drugs to treat hypertension
Diagnostics
Devices such as continuous glucose monitors

The Anti-Diabetes Drugs market in Southeast Asia has been growing steadily over the years, driven by a combination of factors such as changing lifestyles, increasing urbanization, and rising disposable incomes.

Customer preferences: Customers in Southeast Asia are increasingly becoming health-conscious and are taking proactive measures to prevent and manage chronic diseases such as diabetes. As a result, there is a growing demand for anti-diabetes drugs in the region. Additionally, there is a preference for generic drugs due to their lower costs.

Trends in the market: Indonesia is the largest market for anti-diabetes drugs in Southeast Asia, followed by Thailand and the Philippines. The market is dominated by big pharmaceutical companies, with local players also having a significant presence. There is a trend towards the development of new and innovative drugs, with a focus on improving efficacy and reducing side effects. Additionally, there is a growing interest in alternative therapies such as traditional medicine and natural remedies.

Local special circumstances: The prevalence of diabetes in Southeast Asia is high, with the region having one of the highest rates of diabetes in the world. This is due to a combination of factors such as changing diets, sedentary lifestyles, and genetic predisposition. Additionally, there are challenges in accessing healthcare in certain parts of the region, which can impact the availability and affordability of anti-diabetes drugs.

Underlying macroeconomic factors: The Southeast Asian region has been experiencing strong economic growth over the years, which has led to rising disposable incomes and an increase in healthcare spending. Additionally, the region has a large and growing population, which presents a significant market opportunity for pharmaceutical companies. However, there are also challenges such as regulatory barriers and intellectual property issues that can impact the growth of the market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

In 2021, diabetes mellitus caused an estimated 1.62 million deaths worldwide, making it the eighth leading cause of death. Furthermore, it is estimated that 537 million people are currently living with diabetes around the world, with this number projected to rise to some 783 million by the year 2045. Diabetes describes a group of metabolic diseases which cause high blood sugar levels. There are three types of diabetes: type 1 diabetes, type 2 diabetes, and gestational diabetes. However, the majority of diabetes cases are type 2, with an estimated 90 to 95 percent of diabetes cases in the United States type 2. Risk factors for type 2 diabetes include being overweight, being physically inactive, being 45 and older, and having prediabetes.